Agomelatine hepatotoxicity warning

The MHRA has issued updated monitoring guidance for the antidepressant agomelatine.

Agomelatine is an antidepressant indicated for the treatment of major depressive episodes in adults.
Agomelatine is an antidepressant indicated for the treatment of major depressive episodes in adults.

The MHRA has updated the warnings and monitoring guidance for patients treated with agomelatine (Valdoxan) following reports of serious cases of dose-related hepatotoxicity associated with use of the drug.

Liver function tests

The existing recommendations to perform liver function tests in all patients receiving agomelatine at treatment initiation and during treatment have been extended to include testing when the dose is increased.

Prescribers should now perform liver function tests in all patients receiving agomelatine:

  • At initiation of treatment
  • At weeks 3, 6, 12, 24 and periodically thereafter
  • When increasing the dose of agomelatine (at the same time intervals as above)
  • Whenever clinically indicated

In addition:

  • Any patient who develops increased serum transaminases should have their liver function tests repeated within 48 hours
  • Agomelatine should be immediately discontinued if an increase in serum transaminases exceeds three times the upper limit of normal, or if patients present with symptoms or signs of potential liver injury
  • Patients should be informed of the symptoms of potential liver injury and advised to stop taking agomelatine immediately and seek urgent medical advice if these symptoms appear
  • The balance of benefits and risks should be carefully considered before initiating treatment in patients with elevated levels of transaminases pre-treatment or risk factors for hepatic injury
  • Prescribers are reminded that agomelatine is contraindicated in patients with hepatic impairment, ie cirrhosis or active liver disease.

View Valdoxan drug record

Further information: Servier

Follow MIMS on Twitter


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.